Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates

- Daiichi Sankyo, a Japanese pharmaceutical company, is investing approximately 1 billion Euros ($1.07-$1.08 billion USD) to enhance its production and development site near Munich, Germany.
- This investment aims to bolster the creation and manufacturing of antibody-drug conjugates (ADCs) for treating various cancers, including those affecting the breast, lung, and stomach.
- The project is set to create at least 350 new jobs by 2030 and will include the construction of a new laboratory dedicated to ADCs.
- With the expanded capacity, Daiichi Sankyo expects to become a leading player in the regional biotech sector.
- The investment will also strengthen the site's existing cardiovascular drug production, quality assurance, logistics, and sustainability efforts, focusing on renewable energy adoption.
- The expansion process has begun, with work expected to conclude by 2030, while new ADC infrastructure should be ready by the end of 2026.
- Daiichi Sankyo's ADC business is supported by its successful therapy Enhertu (fam-trastuzumab deruxtecan-nxki) and several other investigational ADCs in development.